Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care products behemoth Johnson & Johnson (NYSE:JNJ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at J&J's business and see what CAPS investors are saying about the stock right now.

J&J facts

Headquarters (Founded)

New Brunswick, N.J. (1886)

Market Cap

$178.46 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$60.53 billion

Management

Chairman/CEO William Weldon (since 2002)
CFO Dominic Caruso (since 2007)

Major Brands

Band-Aid, Listerine, Lubriderm, Neutrogena, Sudafed, Tylenol

Return on Equity (Average, Past 3 Years)

24.5%

Cash / Debt

$14.3 billion / $11.6 billion

Dividend Yield

3%

Competitors

Procter & Gamble (NYSE:PG)
Novartis (NYSE:NVS)

CAPS Members Bullish on JNJ Also Bullish on

General Electric (NYSE:GE)

CAPS Members Bearish on JNJ Also Bearish on

Google (NASDAQ:GOOG)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 96% of the 335 members who have rated J&J believe the stock will outperform the S&P 500 going forward. These bulls include bobbyabull and Jim2B.

Just last month, bobbyabull tapped J&J as an essential part of any prudent portfolio: "Great American company; well managed with strong product line, drug pipeline and dividend. A must-own, sleep at night stock that counter-balances that risky small cap you also covet!"

In a pitch from one month earlier, Jim2B elaborates on J&J as an ideal choice for defensive-minded Fools. Here's an excerpt:

[J&J's] sterling financial strength and proven management team provides it a great deal of protection against possible declines in the economy. … Now with the prospect of a government run health care bill raising punitive taxes upon any company in that sector, expect the price to remain depressed until everything sorts out. Still, given the fact that [J&J] has a lot of non-health care related business over which it can distribute those taxes, it should not be as adversely affected as say [Pfizer (NYSE:PFE)] or [Merck (NYSE:MRK)]. … Overall, I'd say that [J&J] is a safe bet with reasonable upside and limited downside.

What do you think about J&J, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson and Procter & Gamble are Motley Fool Income Investor picks, Pfizer is an Inside Value choice, and Google is a recommendation of Rule Breakers. The Fool has a financial position in Johnson & Johnson and Procter & Gamble. The Fool's disclosure policy always gets a perfect score.